ANI Pharmaceuticals (ANIP)

[dasgrunt]

2 i things got out of cc,

mentioned twice ,

"in 2023, we look forward to building on the launch momentum of Cortrophin Gel and acquiring or partnering on other assets that leverage our Rare Disease platform"

what are other assets ?

and

they need to pay down the debt

"So -- well, turning to -- and then on total company cash flows, right, obviously, the second biggest bill, if you will, in 2022 is on debt financing and servicing the debt finance bill. So that cost just shy of $24 million on interest and then $3 million of debt principal pay down. So those are the biggest impacts of cash flow in 2022."